Merck & Co. Inc.’s experimental Covid-19 drug molnupiravir should have similar activity against any new coronavirus variant, a company executive said on NOvember 30.
The latest data from Merck and Ridgeback Biotherapeutics’ MOVe-OUT trial on the use of molnupiravir to treat COVID-19 in adults has shown a lower efficacy than previously reported.
Pfizer plans to seek Emergency Use Authorization (EUA) for an antiviral Covid-19 treatment following an interim analysis of Phase II/III data shown to be statistically and clinically meaningful.
Novavax Inc. said on Oct. 27 the company had completed the real-time submission of an application for the authorization of the Covid-19 vaccine candidate NVX-CoV2373 in the United Kingdom.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee recommended emergency use authorization (EUA) for the Pfizer-BioNTech vaccine for children 5 through 11 years of age, with 17 members voting yes and one abstention.
A booster dose of the Covid-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE restored efficacy to 95.6 percent against the virus, including the Delta variant, data released by the companies from a large study showed on Oct. 21.
Scientists at the U.S. Food and Drug Administration said on Oct. 12 that Moderna Inc. had not met all of the regulatory agency’s criteria to support use of booster doses of the company’s Covid-19 vaccine, possibly because the efficacy of the shot’s first two doses has remained strong.
The effectiveness of the Pfizer Inc./BioNTech SE vaccine in preventing infection by the coronavirus dropped to 47 percent from 88 percent six months after the second dose, according to data published on Oct. 4 that U.S. health agencies considered when deciding on the need for booster shots.
Sage Therapeutics and Biogen announced positive and consistent results from their ongoing clinical trials on the efficacy and safety of zuranolone in treating major depressive disorder (MDD) and postpartum depression (PPD).
AstraZeneca Plc’s Covid-19 vaccine demonstrated 74 percent efficacy at preventing symptomatic disease, a figure that increased to 83.5 percent in people aged 65 and older, according to long-awaited results of the company’s U.S. clinical trial published on Sept. 29